It detects "CD markers" (Clusters of Differentiation). CD34: Signals a primitive, immature cell. CD19/CD20: Confirms a B-cell lineage. CD13/CD33: Points toward myeloid involvement. The Synthesis: A Final Diagnosis
The true power lies in the overlap. A pathologist might see "monomorphous medium-sized blasts" (Morphology) and use Flow Cytometry to confirm they are actually "CD10+ B-lymphoblasts." Flow Cytometry in Neoplastic Hematology Morphol...
Morphology can suggest a lineage, but it cannot always prove it. Two cells might look identical but behave like total strangers. The Molecular Fingerprint (Flow Cytometry) It detects "CD markers" (Clusters of Differentiation)
This is where the story shifts from "how it looks" to "who it is." Flow cytometry acts as a high-speed interrogator for cells. CD13/CD33: Points toward myeloid involvement
Everything begins with a blood smear or bone marrow aspirate. Under the microscope, a pathologist looks for "blasts"—cells that have lost their way. Are the cells abnormally large? The Nucleus: Is the chromatin clumped or fine? The Clues: Presence of Auer rods or specific granules.
As cells pass a laser beam, the machine reads their size (forward scatter) and internal complexity (side scatter).
The microscopic world of hematology is often a battle between what we see and what is actually there. In the diagnosis of neoplastic diseases, the "story" is one of collaboration between traditional morphology and the high-tech precision of flow cytometry. The Visual Clues (Morphology)